


What is claimed is:

1. A crystalline form of the compound of the formula (I)



(I)

which is polymorph B characterized by a X-ray powder diffraction diagram at 25°C and with Copper K alpha 1 as radiation source displaying at least the following reflections, quoted as 2Theta value ± 0.2°:

4,4

8,9

9,7

10,1

12,4

12,9

13,3

14,2

14,7

15,4

16,1

16,4

17,3

17,9

18,3

5	<u>18,4</u>
	<u>18,5</u>
	<u>19,2</u>
	<u>19,4</u>
	<u>19,7</u>
	<u>20,2</u>
	<u>20,6</u>
	<u>21,2</u>
	<u>21,4</u>
	<u>21,9</u>
10	<u>22,3</u>
	<u>22,6</u>
	<u>22,8</u>
	<u>23,6</u>
	<u>24,5</u>
15	<u>24,9</u>
	<u>25,2</u>
	<u>25,5</u>
	<u>25,8</u>
	<u>27,2</u>
20	<u>27,5</u>
	<u>28,8</u>
	<u>29,6</u>
	<u>30,2</u>
	<u>31,2</u>
25	

5

<u>31,5</u>
<u>32,5</u>
<u>33,5</u>
<u>33,9</u>
<u>35,1</u>
<u>36,2</u>
<u>37,6</u>

selected from the group consisting of its polymorph A, its polymorph B and its 1,7-hydrate, or a mixture thereof.

10

2. ~~The form of the compound of claim 1, which is polymorph B.~~

3. ~~The form of the compound of claim 1 which is polymorph B characterized by a X-ray powder diffraction diagram at 25°C and with Copper K alpha 1 as radiation source displaying at least the following reflections, quoted as 2Theta value $\pm$ 0.2°: 9.7, 10.1, 15.4.~~

15

4. ~~The form of the compound of claim 1 which is polymorph B characterized by a X-ray powder diffraction diagram at 25°C and with Cu-K alpha 1 as radiation source displaying at least the following reflections, quoted as 2Theta value $\pm$ 0.2°: 9.7, 10.1, 15.4, 16.1, 20.2.~~

20

5. ~~The form of the compound of claim 1 which is polymorph B characterized by a X-ray powder diffraction diagram at 25°C and with Cu-K alpha 1 as radiation source displaying at least the following reflections, quoted as 2Theta value $\pm$ 0.2°: 9.7, 10.1, 15.4, 16.1, 20.2, 22.3.~~

25

6. ~~The form of the compound of claim 1 which is polymorph B characterized by a X-ray powder diffraction diagram at 25 °C and with Cu-K alpha 1 as radiation source displaying at least the following reflections, quoted as 2Theta value $\pm$ 0.2°: 9.7, 10.1, 15.4, 16.1, 20.2, 22.3, 25.2.~~

7.2. ~~A pharmaceutical composition comprising only one of the crystalline forms selected from the group comprising polymorphic form A, polymorphic form B, and 1,7-hydrate~~

of the compound of the formula (I) as defined in claim 1 mainly and no significant fractions of another form of the compound of the formula (I).

~~8. A pharmaceutical composition comprising a crystalline form of the compound of the formula (I) selected from the group consisting of its polymorphic form A, polymorphic form B, and 1,7 hydrate, its amorphous form or a mixture thereof and further pharmaceutically acceptable excipients.~~

~~9. The pharmaceutical composition of claim 8 comprising only polymorphic form B of the compound of the formula (I) mainly and no significant fractions of another form of the compound of the formula (I).~~

~~10.3.~~ The pharmaceutical composition of claim ~~8-2~~ comprising polymorphic form B of the compound of the formula (I) as defined in claim 1 in more than 85 percent by weight related to the total amount of all forms of the compound of the formula (I) present in the composition.

~~11.4.~~ The pharmaceutical composition of claim ~~10-2~~ comprising polymorphic form B of the compound of the formula (I) as defined in claim 1 in more than 90 percent by weight related to the total amount of all forms of the compound of the formula (I) present in the composition.

~~12.5.~~ A crystalline form of the compound of ~~any of claims 1 to 6~~ for use in therapy.

~~13.6.~~ A pharmaceutical composition of any of claims ~~7-2~~ to ~~11-4~~ for use in therapy.

~~14.7.~~ Use of a compound as defined in ~~any of Claims 1 to 6~~ for the manufacture of a pharmaceutical composition for the treatment or prevention of neoplastic disorders, dermatological disorders, gynaecological disorders, cardiovascular disorders, pulmonary disorders, ophthalmological disorders, neurological disorders, metabolic disorders, hepatic disorders, inflammatory disorders, autoimmune disorders and pain.

~~15.8.~~ Use of a compound as defined in ~~any of Claims 1 to 6~~ for the manufacture of a pharmaceutical composition for the treatment or prevention of lymphoma, macular degeneration, psoriasis, lupus erythematosus, multiple sclerosis, COPD, gout, NASH, hepatic fibrosis, insulin resistance, metabolic syndrome, spondyloarthritis and rheumatoid arthritis, endometriosis and endometriosis-related pain and other

endometriosis-associated symptoms such as dysmenorrhoea, dyspareunia, dysuria and dyschezia.

16.9. Use of a compound as defined in any of Claims 1 to 6 for the manufacture of a stable pharmaceutical composition.